VC-backed AbCellera seeks up to C$500m from IPO: Reuters

Vancouver-based antibody developer AbCellera Biologics said it expects to raise up to C$500 million (US$391 million) in its initial public offering on Nasdaq, Reuters reported.

To read this article, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to read this article and more for free.

Share this